FDA to Begin Acne Drug Registry Next Week
From Times Wire Reports
A registry program intended to prevent use of the acne drug Accutane by pregnant women will begin next week following an earlier delay to address concerns of doctors, federal regulators said. The iPledge system will start Wednesday, the Food and Drug Administration said. The program requires physicians, pharmacies and patients to register if they are to prescribe, sell or take the drug.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
